Literature DB >> 16389329

Quinupristin/dalfopristin: the first available macrolide-lincosamide-streptogramin antibiotic.

C Gurk-Turner1.   

Abstract

Entities:  

Year:  2000        PMID： 16389329      PMCID： PMC1312217          DOI： 10.1080/08998280.2000.11927646

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


× No keyword cloud information.
  20 in total

Review 1.  Gram-positive infections: pharmacy issues and strategy for quinupristin/dalfopristin.

Authors:  J C Rotschafer; D H Wright; G H Brown
Journal:  Diagn Microbiol Infect Dis       Date:  1999-02       Impact factor: 2.803

2.  Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination.

Authors:  S Matsumura; A E Simor
Journal:  Clin Infect Dis       Date:  1998-12       Impact factor: 9.079

3.  Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.

Authors:  G M Eliopoulos; C B Wennersten; H S Gold; T Schülin; M Souli; M G Farris; S Cerwinka; H L Nadler; M Dowzicky; G H Talbot; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 4.  Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.

Authors:  R N Jones; D E Low; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  1999-02       Impact factor: 2.803

5.  Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.

Authors:  C von Eiff; G Peters
Journal:  J Antimicrob Chemother       Date:  1999-04       Impact factor: 5.790

6.  Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia.

Authors:  I Raad; F Bompart; R Hachem
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-03       Impact factor: 3.267

7.  In-vitro activities of 16 non-beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.

Authors:  J Verhaegen; L Verbist
Journal:  J Antimicrob Chemother       Date:  1999-04       Impact factor: 5.790

8.  Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort.

Authors:  P K Linden; A W Pasculle; D McDevitt; D J Kramer
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

9.  Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin.

Authors:  M A Cohen; M D Huband
Journal:  Diagn Microbiol Infect Dis       Date:  1999-01       Impact factor: 2.803

10.  Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.